Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.28
- Piotroski Score 6.00
- Grade Buy
- Symbol (LFCR)
- Company Lifecore Biomedical, Inc.
- Price $7.31
- Changes Percentage (4.66%)
- Change $0.33
- Day Low $7.06
- Day High $7.46
- Year High $8.90
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 01/02/2025
- Fiscal Year End N/A
- Average Stock Price Target $6.50
- High Stock Price Target $8.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.14
- Trailing P/E Ratio -2.76
- Forward P/E Ratio -2.76
- P/E Growth -2.76
- Net Income $12.01 M
Income Statement
Quarterly
Annual
Latest News of LFCR
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Here's Why Greenhaven Road Capital Invested in Lifecore Biomedical (LFCR)
Greenhaven Road Capital's Q3 2024 investor letter highlighted its +15% return for the quarter and +12% year-to-date. The letter discusses top holdings like Lifecore Biomedical, Inc....
By Yahoo! Finance | 1 week ago -
Lifecore Biomedical Inc (LFCR) Q1 2025 Earnings Call Transcript Highlights: Navigating ...
The CEO discusses the Lindy Biosciences opportunity, new wins, and sales team size. The CFO addresses margins and growth strategies. The CEO also mentions development programs and potential reactivati...
By Yahoo! Finance | 1 month ago -
Laughing Water Capital is Waiting for an Investor Update from Lifecore Biomedical (LFCR)
Laughing Water Capital's second-quarter 2024 investor letter highlighted their 2.5% return, focusing on hidden market corners and not investing in mega-cap stocks. They mentioned Lifecore Biomedical, ...
By Yahoo! Finance | 3 months ago
